The global pediatric perfusion market comprises equipment and consumables used for cardiovascular surgeries in children. Pediatric perfusion equipment includes heart-lung machines, oxygenators, blood pumps, and monitoring systems that are specifically designed for pediatric patients. They are safer and better suited for smaller pediatric patients compared to adult cardiopulmonary bypass machines. The growing prevalence of congenital heart diseases is a key factor driving the need for pediatric cardiac surgeries and perfusion care.

The Global Pediatric Perfusion Market is estimated to be valued at US$ 574.7 MN in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period from 2024 to 2031.

Key players operating in the Global Pediatric Perfusion Market Size include Medtronic, GE Healthcare, LivaNova, Inc., Getinge, Braile Biomedica, XENIOS AG, BL Lifesciences, Terumo Corporation, 3M, Koninklijke Philips N.V., EUROSETS, Merck KGaA, Stryker, Cardinal Health, Nonin, and Sorin Group USA, Inc. The growing preference for minimally invasive surgeries and the introduction of innovative perfusion products are supporting the increased adoption of pediatric perfusion services globally. Many companies are also expanding their geographic presence in developing regions to tap the potential opportunities.

Key Takeaways
Key players operating in the pediatric perfusion market are Medtronic, GE Healthcare, LivaNova, Inc., Getinge, Braile Biomedica, XENIOS AG, BL Lifesciences, Terumo Corporation, 3M, Koninklijke Philips N.V., EUROSETS, Merck KGaA, Stryker, Cardinal Health, Nonin, and Sorin Group USA, Inc. The increasing prevalence of congenital heart diseases among children is driving the growth of the market. Various government initiatives and the introduction of pediatric-specific perfusion equipment are also fueling the adoption. Many companies in the market are focusing on new product approvals and launches as well as geographic expansion strategies to strengthen their positions.

The global pediatric perfusion market is witnessing strong growth in demand due to the rising prevalence of pediatric congenital heart diseases. As per the Center for Disease Control and Prevention, congenital heart defects affect nearly 1% of births in the U.S. every year. Early diagnosis and pediatric cardiac surgeries have improved treatment outcomes and quality of life for affected children. At the same time, increasing healthcare expenditure in developing nations is also propelling the market growth.

Market Drivers
The increasing incidence of congenital heart diseases is a key factor driving the growth of the global pediatric perfusion market. As per the WHO, each year around 1.35 million babies are born with a congenital heart anomaly globally. Cardiopulmonary bypass surgeries help repair and correct complex heart defects in pediatric patients. Technological advancements in pediatric cardiac surgery and perfusion care over the past decade have improved safety, efficacy and clinical outcomes. This is encouraging the adoption of perfusion services. Government initiatives focused on creating awareness about congenital heart diseases and their available treatment options are also fueling the market expansion.

Get more insights on This Topic- Global Pediatric Perfusion Market